Company Analysis Integra LifeSciences Holdings Corporation
1. Summary
Advantages
- The stock's return over the last year (-36%) is higher than the sector average (-38.94%).
- Current debt level 40.05% is below 100% and has decreased over 5 years from 43.57%.
- The company's current efficiency (ROE=4.27%) is higher than the sector average (ROE=-80.92%)
Disadvantages
- Price (24.23 $) is higher than fair price (9.92 $)
- Dividends (0%) are below the sector average (1.25%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Integra LifeSciences Holdings Corporation | Healthcare | Index | |
|---|---|---|---|
| 7 days | 38.1% | -3.3% | -0.7% |
| 90 days | -22.3% | -49.8% | 7.7% |
| 1 year | -36% | -38.9% | 30.6% |
IART vs Sector: Integra LifeSciences Holdings Corporation has outperformed the "Healthcare" sector by 2.94% over the past year.
IART vs Market: Integra LifeSciences Holdings Corporation has significantly underperformed the market by -66.6% over the past year.
Stable price: IART is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: IART with weekly volatility of -0.6923% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (24.23 $) is higher than the fair price (9.92 $).
Price is higher than fair: The current price (24.23 $) is 59.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (52.88) is lower than that of the sector as a whole (58.08).
P/E vs Market: The company's P/E (52.88) is higher than that of the market as a whole (47.46).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.26) is lower than that of the sector as a whole (9.43).
P/BV vs Market: The company's P/BV (2.26) is lower than that of the market as a whole (22.53).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.32) is lower than that of the sector as a whole (4.09).
P/S vs Market: The company's P/S indicator (2.32) is lower than that of the market as a whole (15.12).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (16.76) is lower than that of the sector as a whole (17.96).
EV/Ebitda vs Market: The company's EV/Ebitda (16.76) is lower than that of the market as a whole (21.89).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 6.99% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (6.99%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-14.25%).
5.4. ROE
ROE vs Sector: The company's ROE (4.27%) is higher than that of the sector as a whole (-80.92%).
ROE vs Market: The company's ROE (4.27%) is lower than that of the market as a whole (16.98%).
5.5. ROA
ROA vs Sector: The company's ROA (1.79%) is lower than that of the sector as a whole (6.67%).
ROA vs Market: The company's ROA (1.79%) is lower than that of the market as a whole (6.59%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.25%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (137.64%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 19.08.2024 | Mosebrook Jeffrey SVP, Fin & Princ Acct Officer |
Sale | 21.58 | 25 702 | 1 191 |
| 23.05.2024 | ESSIG STUART Exec. Chairman of the Board |
Purchase | 28.49 | 1 499 740 | 52 641 |
| 21.05.2024 | HILL BARBARA B Director |
Purchase | 27.4 | 995 990 | 36 350 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
